Renal Cell Carcinoma Metastatic Clinical Trial
Official title:
Phase II Study for the Evaluation of Neoadjuvant Treatment With Cabozantinib Pior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC).
Metastatic Renal cell carcinoma (RCC) is a type of kidney cancer that arises in the small tubes of the kidneys and has spread to other parts of the body (advanced cancer/metastases). Patients typically have surgery to remove a part or all of their kidney (called partial or radical nephrectomy). Other treatments include chemotherapy, targeted therapy, immunotherapy and hormone therapy and may be used before or after surgery or radiotherapy. There is no standard drug therapy given before surgery, but such preoperative therapy is used widely in the treatment of other cancer types. This approach has several potential advantages, including shrinking the tumor to help improve surgical outcomes and to help find an appropriate drug therapy. Cabozantinib is the generic for the trade chemotherapy drug CABOMETYX™ (cabozantinib). It is known as a cancer growth inhibitor and also an angiogenesis inhibitor. Tyrosine kinases are proteins that control how cells grow and divide. By blocking the activity of these proteins in cancer cells, the medicine reduces the growth and spread of cancer. This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05548621 -
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
|
||
| Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
| Completed |
NCT06161233 -
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
|
N/A | |
| Not yet recruiting |
NCT06321250 -
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04764487 -
A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
|
Phase 3 | |
| Active, not recruiting |
NCT03905889 -
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT03977571 -
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
|
N/A | |
| Completed |
NCT03699579 -
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
|
||
| Terminated |
NCT05103722 -
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
|
N/A |